{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Lenvatinib vs. Sorafenib as First-Line Treatment for Unresectable HCC
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Description
Method of Participation in the Learning Process/Evaluation Method Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form. Getting the Most out of the Activity As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed.Accreditation Statement:
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.Purpose of Activity
To provide information on the use of lenvatinib as first-line treatment and other, second-line treatments, for unresectable hepatocellular carcinoma (HCC).Learning Objectives
After completing this continuing education activity you will be able to:
- Propose encouraging second-line treatments for HCC patients having prior sorafenib therapy.
- Appraise the results of the phase 3 evaluation of lenvatinib vs. sorafenib as first-line treatment for unresectable HCC.
Disclosures
The author, faculty, staff, and planners have no relevant financial relationship with any ineligible organizations regarding this educational activity.
Price:
$10.00
Credits:
- ACPE 1.0 CH
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. AUN# 0431-0000-22-020-H04-P
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Professions:
Pharmacist
Test Code: OT1218P
Published: April 2019
Expires: 9/13/2025
Sources:
Allied Health Collection
Required Passing Score: 8/10 (80%)
Categories:
Pharmacology